British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.
St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK. catherine.smith@kcl.ac.uk
C H
CH
Smith
A V
AV
Anstey
J N W N
JN
Barker
A D
AD
Burden
R J G
RJ
Chalmers
D A
DA
Chandler
A Y
AY
Finlay
C E M
CE
Griffiths
K
K
Jackson
N J
NJ
McHugh
K E
KE
McKenna
N J
NJ
Reynolds
A D
AD
Ormerod
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003880:Dermatology / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011247:Pregnancy; D011565:Psoriasis / Q000150:complications / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014777:Virus Diseases / Q000150:complications / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha